Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18157890 | 0.77 | CNR2 (0.44) | CNR2ACHEHTR7HTR1AHTR2A | |
| SCHEMBL6840526 | 0.77 | CNR2 (0.44) | CNR2ACHEHTR7HTR1AHTR2A | |
| SCHEMBL4008375 | 0.76 | — | — | |
| SCHEMBL13593108 | 0.75 | CNR2 (0.43) | CNR2ACHEHTR7HTR1AHTR2A | |
| SCHEMBL8014414 | 0.75 | CNR2 (0.43) | CNR2ACHEHTR7HTR1AHTR2A | |
| Methane SCHEMBL11276226 | 0.73 | CNR2 (0.53) | CNR2ACHEHTR7HTR1AHTR2A | |
| SCHEMBL1533682 | 0.73 | — | — | |
| SCHEMBL4700565 | 0.72 | CNR2 (0.31) | CNR2 | |
| SCHEMBL9839846 | 0.72 | CNR2 (0.41) | CNR2ACHE | |
| SCHEMBL8027980 | 0.72 | ALDH1A1 (0.41) | CNR2ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CNR2 567/4885ACHE 4877/4885HTR7 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.